Seppo Yl?-Herttuala | Author | SciTechnol

Seppo Yl?-Herttuala Author

seppo.ylaherttuala@uef.fi +358 40 355 2075 | +358 40 355

Subjects of specialization
VEGF , Gene therapy, Safety

Affiliation
Research Unit, Kuopio University Hospital, Kuopio, Finland

Biography

Academy Professor Seppo Ylä-Herttuala is a pioneer and international leader in cardiovascular gene therapy. He was the first in the world to apply adenoviral gene transfer to human arteries in 1995. Since then he has developed both gene transfer vectors and production systems and a highly successful research team focusing on angiogenesis, VEGF biology and its clinical applications.

Publications

Research Article Open Access

Intramyocardial Adenovirus-Mediated VEGF-DÎ”NÎ”C Gene Transfer in Patients with No-Option Coronary Artery Disease: Interim Safety Analysis of the Kuopio Angiogenesis Trial 301

Author(s):

Kirsi Muona, Marja Hedman, Antti Kivel?, Antti Hedman,Iiro Hassinen, Juha Hartikainen and Seppo Yl?-Herttuala

Intramyocardial Adenovirus-Mediated VEGF-DΔNΔC Gene Transfer in Patients with No-Option Coronary Artery Disease: Interim Safety Analysis

VEGF- mediated gene therapy is a potential new treatment for patients with advanced cardiovascular diseases. However, previous clinical trials have not been able to convincingly demonstrate the efficiency of VEGF gene therapy in humans. Low gene transfer efficiency and insufficient gene expression time could be major contributing factors. To improve these shortcomings we have started a new intramyocardial gene therapy tr... view more»

DOI: 10.4172/2324-8602.1000150

Abstract HTML PDF